Health · 1 sources covering this

STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field

The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines. They could also have a chilling effect across the industry.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·59m ago
STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines. They could also have a chilling effect across the industry.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/b5808ff2f9d8afa0feb8f8376562f8cb1603377e"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field"></iframe>

STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field

How 1 sources are covering this

STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field

More from Health

Readers Wrestle With Healthcare Inequalities and Want a Word With Congress

Indigenous Groups Are Exempt From Medicaid Work Rules, but Native Hawaiians Aren’t

Opinion: I’m a thoracic surgeon in New York City. For many of my patients, Sept. 11 is still not over

Opinion: I’m a public health communications consultant. Pro-vaccine advocacy needs more fun

Reader

Trust & legal

Across the network